Gedeon Richter is to enhance its existing branded female healthcare franchise worldwide and tap into transdermal patch formulations after signing an agreement to acquire Janssen’s Evra (ethinyl estradiol/norelgestromin) outside of the US for $263.5m.
The Johnson & Johnson subsidiary is to provide support to Richter to smooth the transfer of the marketing authorizations, including in the transaction a transitional business license agreement and “series of other related
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?